News

COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…

COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Overview Presented at Calicivirus Conference On September 12, ...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Confer…

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation ...